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patients: 80 males, 62 females, median age 64 (35-83), stage 
3A (83 pts) or 3B (59 pts). Patients received 2 cycles of C 
AUC=5 IV on day 1 and G 1000mg/m2 IV on days 1 and 8 every 
3 weeks x 2, followed on day 50 by CRT, 60Gy/30 over 6 
weeks, concomitantly with P 50mg/m2 IV and G 100mg/m2 IV 
on days 1 and 8 every three weeks x 2 cycles. 
Results: The median overall survival was 23 months. With a 
median follow-up of 54 months, the 3, 4 and 5 year overall 
survival was 37% (38 pts remaining), 27% (21 pts), and 23% (15 
pts) respectively. The median and 5 year progression-free 
survival rates were 11 months and 21% respectively. Rates of 
acute grade ≥ 3 hematological, esophageal and respiratory 
toxicity were, respectively, 20%, 8% and 7%. Forty-eight 
patients received further lines of chemotherapy. 
Conclusions: The results of the present analysis based on 142 
stage 3 NSCLC patients treated with this novel induction 
chemotherapy approach affirm its favourable toxicity profile 
without apparent compromise in clinical outcomes. Indeed, 
although the development of this regimen was motivated by 
delays to prompt commencement of CRT, the observed 
outcomes do compare favourably with those associated with 
immediate concurrent CRT regimens.  
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Purpose/Objective: Decision Support Systems, based on 
statistical prediction models, have the potential to change 
the way medicine is being practiced, but their application is 
currently hampered by the astonishing lack of impact studies. 
The main goal of this project aims to develop a scalable 
infrastructure to integrate translational research into the 
clinical decision making process in lung cancer.  
Materials and Methods: To develop this infrastructure, it was 
decided to use an integration based on free software tools. 
Among them, the management system for clinical trials, 
OpenClinica, provides mechanisms for the definition of 
electronic records and collection of cancer information 
relevant to research studies, as well as offers techniques for 
managing and maintaining the data. Additionally, for 
achieving a clinical decision support, we incorporated tools 
that provide mechanisms for data mining processes. The 
architecture also integrates a software for biomedical 
informatics research: i2b2. Information from different data 
sources such as the information recorded from the electronic 
health records of OpenClinica was stored centrally in a data 
warehouse. Finally, a tool integrates the mechanisms for 
analysis and data mining. Two different approaches are used 
for this task: RapidMiner to implement the algorithms of data 
mining and data analysis; and the business rule definition in 
JBoss Guvnor for process modeling in relation to the oncology 
clinical guide. With these two tools clinicians can receive 
recommendations based on both clinical data and decisional 
algorithms defined by international treatment guidelines. 
Results: The recruitment from January 1, 2013 until 
September 1, 2014 comprises the clinical data from 163 lung 
cancer patients treated with radio(chemo)therapy. Genetic 
data come from another operating system and includes 
genotypes at 3 single nucleotide polymorphisms of the HSPB1 
gene which has been found to be associated survival after 
using the data mining tool. Finally, the dosimetric data are 
exported from radiotherapy treatment planning systems. 
Currently, we are integrating the information mentioned 
before with the clinical decision support algorithms based on 
international treatment guidelines. 
Conclusions: The development of infrastructures based on 
the integration of systems able to interoperate between each 
other will favor the agile integration between the classical 
research and the clinical practice, allowing the customization 
of treatments.  
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Purpose/Objective: In patients treated with lung 
stereotactic body radiation therapy (SBRT), dynamic tumor 
tracking technique (DTT) can potentially improve accuracy of 
treatment and allow reduction of dose to the surrounding 
organs at risk (OARs). In Vero4DRT, the DTT can be 
performed by using its unique gimbaled linac system. The 
purpose of this study is to assess the technical advantages of 
DTT in lung SBRT when compared to treatment without DTT 
(static SBRT planning) on the Vero4DRT platform.  
Materials and Methods: Thirteen patients from our 
institution treated with lung SBRT with DTT by Vero4DRT 
between March 2013 and September 2014 were included in 
this study. All patients underwent the same planning process 
detailed below. For each patient, an SBRT plan without DTT 
was created using the same CT images and compared with 
the actual treatment plan. Prior to CT simulation, fiducial 
markers were inserted around the tumor via bronchoscopy. 
During CT simulation, a planning CT was first obtained in the 
expiratory phase using a respiratory gating system, followed 
by a 4D-CT scan. GTV was then delineated on the planning 
CT. For DTT SBRT, ITV was defined as GTV plus uncertainty of 
distances from the center of the GTV to the center of the 
fiducial markers calculated in all phases of 4D-CT. PTV (tPTV) 
was created by adding an individualized margin to account 
for uncertainties of 4D respiratory model and other 
mechanical errors. For static SBRT, ITV was the summation of 
GTV positions in all phases of 4D-CT, and the PTV (sPTV) was 
defined as ITV plus 5mm margin for set-up errors. The 
prescription dose was 50 Gy in 4 fractions (D95 prescription) 
to both tPTV and sPTV. To assess the technical advantage of 
DTT SBRT, the PTV volumes and V20 of the lung for both sets 
of plans were compared.  
Results: The median tumor diameter and respiratory motion 
in all patients was 30mm (12-48mm) and 17mm (4-31mm) 
respectively. The mean volumes of tPTV and sPTV were 
32.6ml and 49.8ml respectively, corresponding to an average 
reduction of 28.7 ± 8.0% (p = 0.0003) in the tPTV compared 
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to sPTV. The mean V20 values was 7.8% for dynamic tracking 
SBRT (tV20) and 8.1% for static SBRT (sV20), corresponding to 
an average reduction of 11.2 ± 5.9% (p = 0.016) in the tV20 
compared to sV20. 
Conclusions: This study demonstrates that lung SBRT with 
DTT reduces treatment volumes and dose to normal lung 
tissue. Further clinical outcome data are required to validate 
these findings.  
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Purpose/Objective: Radiotoxicity during radiotherapy of lung 
cancer may be misdiagnosed as pneumonia or respiratory 
tract infections which prevents the patients from getting 
optimal treatment. We evaluated changes of three 
inflammation-associated cytokines in patients undergoing 
radiotherapy for non-small cell lung cancer (NSCLC) to 
establish changes of their levels and evaluate which of the 
markers: Interleukin 6 (IL-6), Tumour necrosis factor-alpha 
(TNF-a) or Lipopolysaccharide-binding protein (LBP) are 
specifically affected by radiation dose received by the 
pulmonary and mediastinal structures rather than infection. 
Materials and Methods: In this pilot phase of the project we 
evaluated 29 patients treated for NSCLC by means of 
2.0Gy/daily schemes with total target doses in the range of 
60-74Gy. Cytokines were measured before start of treatment, 
on the day of reaching the total dose of 20Gy and at 40Gy. An 
age-matched control group of 8 individuals was used to 
establish differences in baseline cytokine levels. Data from 
the 40Gy time-point were correlated with histogram 
parameters of the radiotherapy protocol. ELISA kits were 
used for cytokine quantification (IL-6 and TNF-a by R&D, USA 
and LBP by Abnova, Taiwan). Arithmetical means were used 
for LBP, while geometrical means were used to represent 
results of IL-6 and TNF-a due to non-normal distribution of 
values. 
Results: Average age of the group was 64.61+/-6.57 years, 
majority of patients were male (18 vs 11). The group with 
NSCLC showed higher than controls baseline levels of IL-6 
(5.11+/-2.52 vs 2.18+/-2.19; p=0.02) and marginally higher 
TNF-a (17.94+/-1.16 vs 16.30+/-1.17; p=0.12). No such 
differences were seen in LPB levels (35.86+/-8.45 vs 32.69+/-
9.38; p=0.36). Levels of all three cytokines remained 
unchanged during treatment: IL-6 5.11+/-2.52; 4.59+/-1.86 
and 6.15+/-4.00 (p=0.25); TNF-a 17.94+/-1.16; 17.56+/-1.18 
and 19.88+/-1.74 (p=0.47); LBP 35.87+/-8.45; 35.72+/-7.58 
and 35.82+/-7.06 (p=0.36). However, at the 40Gy timepoint, 
positive, significant correlations were noted for LBP and lung 
volume subjected to 5Gy (r=0.52, p=0.01), 20Gy (r=0.41, 
p=0.049) and mean radiation dose planned for lung tissue 
(r=0.49, p=0.02, Figure 1). Neither IL-6 nor TNF-a showed 
such associations, hinting at the specificity of LBP reaction to 
lung irradiation. 
 
 
Conclusions: LBP levels correlate with radiation exposure of 
pulmonary tissue regardless of infectious causes and can be 
used for further studies on radiotoxicity in NSCLC patients. 
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Purpose/Objective: Patients with lung cancer undergoing 
radiotherapy (RT) are at risk of lung-related toxicity such as 
radiation pneumonitis (RP). It has been reported that RP 
occurs after initiation of radiotherapy for a wide range of 
doses in the normal lung tissue. In addition to RT, the effect 
of targeted therapy such as erlotinib on normal lung needs to 
be considered. Medical imaging may be employed for 
detection of normal tissue effects from RT and erlotinib. This 
